A Pilot Study to Examine the Effect of Pea Protein on Limiting the Loss of Muscle Mass During Weight Loss
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Manitoba
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Change in muscle mass
Overview
Brief Summary
A pilot study comparing the effects of pea protein versus whey protein on the preservation of muscle mass and functionality in individuals undertaking a weight loss regimen.
Detailed Description
A single site, double-blind, randomized clinical trial designed to compare the effects of pea protein or whey protein or maltodextrin supplementation on muscle mass and functionality in males and females with obesity undertaking a weight loss regimen. Eligible participants will be randomized to one of the three groups (pea protein, whey protein, maltodextrin) and will be asked to attend 3 in-person clinic visits (0, 6, and 12 weeks) for blood and urine collection and assessments of muscle mass and muscle function. A separate visit for screening and for a fasting blood sample, as well as a Pre-Study visit and a meeting with a registered dietitian, will be required.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 30 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male, or non-pregnant, non-lactating female, 30 to 50 years of age;
- •BMI \>30 and body weight does not exceed the capacity of the DEXA (350 lbs);
- •Fat mass \>23% for males and \>32% for females (determined at the screening visit via bioelectrical impedance);
- •Willing to maintain a stable level of activity while participating in the study;
- •Plasma creatinine ≤265 µmol/L;
- •Plasma LDL-cholesterol \<5 mmol/L;
- •Aspartate aminotransferase \<160 U/L, and alanine aminotransferase \<150 U/L;
- •Glycated hemoglobin \<6.5%;
- •Blood pressure \<160 mmHg systolic and \<100 mmHg diastolic;
- •Stable regime if taking vitamin and mineral/dietary/herbal supplements for the past 1 month and while participating in the study;
Exclusion Criteria
- •Has experienced a cardiovascular event (e.g. heart attack, stroke) or had a surgical procedure for cardiovascular disease (e.g. bypass, stent), presence of diabetes, chronic renal disease, liver disease (with exception of fatty liver), rheumatoid arthritis, immune disorder or disease (e.g. multiple sclerosis, leukemia), cancer in the previous 5 years, neurological disorders, gastrointestinal disorders or gastrointestinal surgery or bariatric surgery, or liposuction;
- •Taking medications for blood glucose management;
- •Taking medications or natural health products/supplements associated with weight gain or weight loss (e.g. prednisone, certain cold medications);
- •Body weight that has not been stable (± 5%) over the past 3 months;
- •History of gastrointestinal reactions or allergies to peas, pea protein, whey protein or maltodextrin, or to one or more ingredients in the beverages and foods that will be provided which significantly limits the number of items that can be used for delivery of the protein powders or maltodextrin;
- •Current (within the past 30 days) bacterial, viral or fungal infection;
- •Uncontrolled hypothyroidism;
- •Uncontrolled blood pressure;
- •Bleeding disorder;
- •Any acute medical condition or surgical intervention within the past 3 months;
Outcomes
Primary Outcomes
Change in muscle mass
Time Frame: Baseline and 12 weeks
Muscle mass will be assessed by dual x-ray absorptiometry
Change in muscle function (hand grip)
Time Frame: Baseline and 12 weeks
A dynamometer will be used to measure hand grip strength
Change in muscle function (gait test)
Time Frame: Baseline and 12 weeks
A gait test will be performed
Secondary Outcomes
- Change in C-reactive protein(Baseline and 12 weeks)
- Change in liver function (based on profile of circulating markers)(Baseline and 12 weeks)
- Change in kidney function (based on profile of urinary markers)(Baseline and 12 weeks)
- Changes in blood vessel function(Baseline and 12 weeks)
- Change in kidney function (based on profile of circulating markers)(Baseline and 12 weeks)
- Change in systolic and diastolic blood pressure(Baseline and 12 weeks)
- 24 h activity patterns over time(Up to 12 weeks)
- Change in fat mass(Baseline and 12 weeks)
- Change in waist and waist to height ratio(Baseline and 12 weeks)
- Change in homeostatic model for insulin resistance (HOMA-IR)(Baseline and 12 weeks)
- Food intake over time(Up to 12 weeks)
- Change in body weight and body mass index(Baseline and 12 weeks)
- Change in resting energy expenditure(Baseline and 12 weeks)
- Change in glycated hemoglobin(Baseline and 12 weeks)
- Change in blood lipid profile(Baseline and 12 weeks)
Investigators
Dr. Peter Zahradka
Principal Investigator
University of Manitoba